

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8201266

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
PFENEX INC.	07/25/2023

RECEIVING PARTY DATA

Name:	PELICAN TECHNOLOGY HOLDINGS, INC.
Street Address:	10790 ROSELLE STREET,
City:	SAN DIEGO
State/Country:	CALIFORNIA
Postal Code:	92121

PROPERTY NUMBERS Total: 48

Property Type	Number
Application Number:	60914361
Application Number:	12109554
Application Number:	15384029
Application Number:	12610207
Application Number:	60537148
Application Number:	11400840
Application Number:	15230192
Application Number:	11038901
Application Number:	13039183
Application Number:	60523420
Application Number:	12512930
Application Number:	60524124
Application Number:	10996007
Application Number:	60591489
Application Number:	11189375
Application Number:	14071273
Application Number:	60687763
Application Number:	11447553
Application Number:	12330723
Application Number:	60887476

PATENT

Property Type	Number
Application Number:	60887486
Application Number:	12022789
Application Number:	12604061
Application Number:	60809536
Application Number:	11809100
Application Number:	61320239
Application Number:	13076315
Application Number:	61319152
Application Number:	61325235
Application Number:	13073955
Application Number:	13952484
Application Number:	61641105
Application Number:	13844261
Application Number:	14842672
Application Number:	62086119
Application Number:	14954766
Application Number:	16135875
Application Number:	62578302
Application Number:	16163398
Application Number:	16849532
Application Number:	62578304
Application Number:	16163421
Application Number:	63209239
Application Number:	17836919
PCT Number:	US2022032911
PCT Number:	US2022032212
PCT Number:	US2005001549
PCT Number:	US2008061483

CORRESPONDENCE DATA

Fax Number: (404)853-8806

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4048538000

Email: patentdocket@eversheds-sutherland.com,
ArdithChang@eversheds-sutherland.us,
RandyLeshin@eversheds-sutherland.us

Correspondent Name: EVERSHEDES SUTHERLAND (US) LLP

Address Line 1: 999 PEACHTREE STREET N.E.

Address Line 2: SUITE 2300

Address Line 4: ATLANTA, GEORGIA 30309

ATTORNEY DOCKET NUMBER:	94931-0001
NAME OF SUBMITTER:	ARDITH CHANG
SIGNATURE:	/Ardith Chang/
DATE SIGNED:	10/03/2023

Total Attachments: 63

source=Project Pelican - IP Assignment (Executed)_Redacted#page1.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page2.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page3.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page4.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page5.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page6.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page7.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page8.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page9.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page10.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page11.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page12.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page13.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page14.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page15.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page16.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page17.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page18.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page19.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page20.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page21.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page22.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page23.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page24.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page25.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page26.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page27.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page28.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page29.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page30.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page31.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page32.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page33.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page34.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page35.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page36.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page37.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page38.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page39.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page40.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page41.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page42.tif

source=Project Pelican - IP Assignment (Executed)_Redacted#page43.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page44.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page45.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page46.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page47.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page48.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page49.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page50.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page51.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page52.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page53.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page54.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page55.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page56.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page57.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page58.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page59.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page60.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page61.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page62.tif
source=Project Pelican - IP Assignment (Executed)_Redacted#page63.tif

INTELLECTUAL PROPERTY ASSIGNMENT

THIS INTELLECTUAL PROPERTY ASSIGNMENT (this "Assignment") is made and entered into as of July 25, 2023, by and between by and between Pfenex Inc., a Delaware corporation (the "Assignor"), and Pelican Technology Holdings, Inc., a Delaware corporation and direct wholly-owned subsidiary of the Assignor (the "Assignee"). The Assignor and the Assignee are sometimes referred to herein individually as a "Party" and collectively as the "Parties".

WHEREAS, Assignor and Assignee have entered into that certain Contribution, Assignment and Assumption Agreement dated as of July 25, 2023 (the "Contribution Agreement"); and

WHEREAS, pursuant to the terms of the Contribution Agreement, the Assignor agreed to, among other things, contribute, assign, transfer, convey and deliver to the Assignee all of Assignor's right, title, and interest in and to the Assigned Assets, including without limitation the Intellectual Property listed on Schedule A (collectively referred to as the "Assigned Intellectual Property").

NOW, THEREFORE, in consideration of the promises, covenants and representations set forth herein and in the Contribution Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:

1. The following term shall have the meanings set forth below. Unless otherwise defined herein, capitalized terms used herein shall have the meanings assigned to such terms in the Contribution Agreement.

a. "Intellectual Property" means all (a) discoveries and inventions (whether patentable or unpatentable and whether or not reduced to practice), improvements thereto, and patents, patent applications (either filed or in preparation for filing), patent disclosures and statutory invention registrations, together with reissuances, divisions, continuations, continuations-in-part, revisions, extensions and reexaminations thereof, (b) trademarks, service marks, trade dress, logos, trade names, corporate names, domain names and source identifiers, together with translations, adaptations, derivations and combinations thereof, and including goodwill associated therewith, and applications (either filed or in preparation for filing), registrations and renewals in connection therewith, and reissues, extensions and renewals of any of the foregoing, (c) copyrightable works, copyrights (whether or not registered) and applications (either filed or in preparation for filing), registrations and renewals in connection therewith, and reissues, extensions and renewals of any of the foregoing, (d) trade secrets and confidential and proprietary business information (including ideas, research and development, know-how, formulas, compositions, manufacturing and production processes and techniques, technical data, designs, drawings, specifications, customer and supplier lists, pricing and cost information, and business and marketing plans and proposals), whether or not patentable and whether or not reduced to practice, (e) other proprietary rights relating to any item described in the immediately preceding clauses (a) through (d), including remedies against infringements thereof and rights of protection of an interest therein under the laws of all jurisdictions (including rights provided by

common law or by international treaties or conventions), and (f) copies and tangible embodiments of any item described in the immediately preceding clauses (a) through (d).

2. The Assignor hereby contributes, assigns, transfers, conveys and delivers to the Assignee, and its successors and assigns, and Assignee hereby accepts and acquires from Assignor and takes assignment and delivery of all of Assignor's right, title, and interest in and to the Assigned Intellectual Property, including all goodwill associated therewith, all copyrights included therein, all royalties, fees, income, payments, and other proceeds now or hereafter due or payable with respect thereto, and all rights to sue and recover remedies resulting from the past and future infringement thereof, whether accruing before, on or after the date hereof.

3. The Assignor shall execute and deliver any and all instruments and documents, including confirmatory assignments suitable for recording in the relevant international jurisdictions, and take such further actions as may be necessary or reasonably requested by the Assignee to document and record with the appropriate authorities the aforesaid assignment and transfer. Without limiting the foregoing, Assignor shall take all steps as may be reasonably necessary to effect assignment and transfer of any domain names included in the Assigned Intellectual Property in accordance with the domain name transfer procedures of the applicable registrar(s) for such domain names.

4. All issues and questions concerning the construction, validity, interpretation and enforceability of this Assignment and the exhibits hereto, and all claims and disputes arising hereunder or thereunder or in connection herewith or therewith, whether purporting to be sound in contract or tort, or at law or in equity, shall be governed by, and construed in accordance with, the laws of the State of Delaware, without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware. The Parties hereby agree and consent to be subject to the exclusive jurisdiction of the United States District Court for the District of Delaware, and in the absence of such federal jurisdiction, the Parties consent to be subject to the exclusive jurisdiction of the state courts located in Wilmington, Delaware, and hereby waive the right to assert the lack of personal or subject matter jurisdiction or improper venue in connection with any such suit, action or other proceeding. In furtherance of the foregoing, each of the Parties (i) waives the defense of inconvenient forum, (ii) agrees not to commence any suit, action or other proceeding arising out of this Assignment or any transactions contemplated hereby other than in any such court, and (iii) agrees that a final judgment in any such suit, action or other proceeding shall be conclusive and may be enforced in other jurisdictions by suit or judgment or in any other manner provided by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY LITIGATION, ACTION, PROCEEDING, CROSS-CLAIM, OR COUNTERCLAIM IN ANY COURT (WHETHER BASED ON CONTRACT, TORT, OR OTHERWISE) ARISING OUT OF, RELATING TO OR IN CONNECTION WITH (i) THIS ASSIGNMENT OR THE VALIDITY, PERFORMANCE, INTERPRETATION, COLLECTION OR ENFORCEMENT HEREOF OR (ii) THE ACTIONS OF SUCH PARTY IN THE NEGOTIATION, AUTHORIZATION, EXECUTION, DELIVERY, ADMINISTRATION, PERFORMANCE OR ENFORCEMENT HEREOF.

5. Whenever possible, each provision of this Assignment will be interpreted in such

manner as to be effective and valid under applicable law, but if any provision of this Assignment is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Assignment will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.

6. This Assignment may be executed in any number of counterparts (including by means of facsimile or email if in .pdf format), each of which shall be deemed an original instrument but all of which together shall together constitute one and the same agreement.

7. To the extent any term, condition, or provision of this Assignment is in any way inconsistent with or in conflict with any term, condition or provision of the Contribution Agreement, the Contribution Agreement shall govern and control.

[THE REMAINDER OF THIS PAGE IS LEFT INTENTIONALLY BLANK]

IN WITNESS WHEREOF, the Parties hereto have caused this Assignment to be duly executed and delivered as of the date first written above.

ASSIGNOR:

PFENEX INC.

DocuSigned by:
By Matthew Korenberg
3A4206EDE169402...

Name: Matthew Korenberg

Title: President

ASSIGNEE:

PELICAN TECHNOLOGY HOLDINGS, INC.

DocuSigned by:
By Matthew Korenberg
3A4206EDE169402...

Name: Matthew Korenberg

Title: President

[Signature Page to IP Assignment]

Schedule A
Assigned Intellectual Property

See attached.

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
65569: METHOD FOR RAPIDLY SCREENING MICROBIAL HOSTS TO IDENTIFY CERTAIN STRAINS WITH IMPROVED YIELD AND/OR QUALITY IN THE EXPRESSION OF HETEROLOGOUS PROTEIN					
AU	PCT	Granted	2008245696	2008245696	PCT/US08/61483 (4/25/2008)
CA	DIV	Granted	2964910	2964910	PCT/US08/61483 (4/25/2008)
EP	PCT	Granted	8746833.6	2142651	PCT/US08/61483 (4/25/2008)
AT	EP	Validated	8746833.6	2142651	PCT/US08/61483 (4/25/2008)
BE	EP	Validated	8746833.6	2142651	PCT/US08/61483 (4/25/2008)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
FR	EP	Validated	8746833.6	2142651	PCT/US08/61483 (4/25/2008)
DE	EP	Validated	8746833.6	60 2008 024 803.8 (2142651)	PCT/US08/61483 (4/25/2008)
GB	EP	Validated	8746833.6	2142651	PCT/US08/61483 (4/25/2008)
IE	EP	Validated	8746833.6	2142651	PCT/US08/61483 (4/25/2008)
IT	EP	Validated	8746833.6	502013902178684 (2142651)	PCT/US08/61483 (4/25/2008)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
CH	EP	Validated	8746833.6	2142651	PCT/US08/61483 (4/25/2008)
TR	EP	Validated	8746833.6	2142651	PCT/US08/61483 (4/25/2008)
NL	EP	Validated	8746833.6	2142651	PCT/US08/61483 (4/25/2008)
IN	PCT	Granted	6791/DELNP/2009	278242	PCT/US08/61483 (4/25/2008)
JP	PCT	Granted	2010-506503	544553	PCT/US08/61483 (4/25/2008)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
KR	PCT	Granted	10-2009-7024636	10-1530395	PCT/US08/61483 (4/25/2008)
SG	PCT	Granted	200906987.3	156356	PCT/US08/61483 (4/25/2008)
US	PRO	Expired	60/914361		
US	ORD	Granted	12/109554	9394571	
US	CIP	Granted	12/610207	9580719	

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
US	DIV	Granted	15/384029	10689640	
63622: EXPRESSION OF MAMMALIAN PROTEINS IN PSEUDOMONAS FLUORESCENS					
AU	PCT	Granted	2005206951	2005206951	PCT/US05/01549 (1/18/2005)
CA	PCT	Granted	2553503	2553503	PCT/US05/01549 (1/18/2005)
EP	PCT	Granted	05705852.1	1709170	PCT/US05/01549 (1/18/2005)
AT	EP	Validated	05705852.1	1709170	PCT/US05/01549 (1/18/2005)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
BE	EP	Validated	05705852.1	1709170	PCT/US05/01549 (1/18/2005)
FR	EP	Validated	05705852.1	1709170	PCT/US05/01549 (1/18/2005)
DE	EP	Validated	05705852.1	60 2005 053 517.9 (1709170)	PCT/US05/01549 (1/18/2005)
GB	EP	Validated	05705852.1	1709170	PCT/US05/01549 (1/18/2005)
IE	EP	Validated	05705852.1	1709170	PCT/US05/01549 (1/18/2005)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
IT	EP	Validated	05705852.1	502018000009619 (1709170)	PCT/US05/01549 (1/18/2005)
NL	EP	Validated	05705852.1	1709170	PCT/US05/01549 (1/18/2005)
PL	EP	Validated	05705852.1	1709170	PCT/US05/01549 (1/18/2005)
ES	EP	Validated	05705852.1	1709170	PCT/US05/01549 (1/18/2005)
CH	EP	Validated	05705852.1	1709170	PCT/US05/01549 (1/18/2005)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
TR	EP	Validated	05705852.1	1709170	PCT/US05/01549 (1/18/2005)
EP	DIV	Granted	11176612.7	2434016	PCT/US05/01549 (1/18/2005)
GB	DIV	Validated		2434016	PCT/US05/01549 (1/18/2005)
IE	DIV	Validated		2434016	PCT/US05/01549 (1/18/2005)
ES	DIV	Validated		2434016	PCT/US05/01549 (1/18/2005)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
FR	DIV	Validated		2434016	PCT/US05/01549 (1/18/2005)
DE	DIV	Validated		602005054961.7 (2434016)	PCT/US05/01549 (1/18/2005)
AT	DIV	Validated		2434016	PCT/US05/01549 (1/18/2005)
IN	PCT	Granted	3608/DELNP/2006	252620	PCT/US05/01549 (1/18/2005)
JP	PCT	Granted	2006-549690	5602336	PCT/US05/01549 (1/18/2005)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
KR	PCT	Granted	10-2006-7014191	10-1183720	PCT/US05/01549 (1/18/2005)
SG	PCT	Granted	200604702.1	124020	PCT/US05/01549 (1/18/2005)
US	PRO	expired	60/537,148		
US	CON	Granted	11/400840	9458487	
US	CIP	Granted	11/038901	9453251	

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
US	CON	Granted	15/230,192	10041102	
PF0005: METHOD FOR PRODUCING SOLUBLE RECOMBINANT INTERFERON PROTEIN WITHOUT DENATURING					
US	ORD	Granted	13/039183	9187543	
62716: IMPROVED PROTEIN EXPRESSION SYSTEMS					
AU	PCT	Granted	2004293810	2004293810	PCT/US04/38884 (11/19/2004)
CA	PCT	Granted	2545610	2545610	PCT/US04/38884 (11/19/2004)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
CN	PCT	Granted	200480040702.7	ZL200480040702.7	PCT/US04/38884 (11/19/2004)
EP	PCT	Granted	04811581.1	1692282	PCT/US04/38884 (11/19/2024)
GB	EP	Validated	04811581.1	1692282	PCT/US04/38884 (11/19/2024)
FR	EP	Validated	04811581.1	1692282	PCT/US04/38884 (11/19/2024)
IT	EP	Validated	04811581.1	1692282	PCT/US04/38884 (11/19/2024)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
DE	EP	Validated	04811581.1	602004038866.1 (1692282)	PCT/US04/38884 (11/19/2024)
IE	EP	Validated	04811581.1	1692282	PCT/US04/38884 (11/19/2024)
CH	EP	Validated	04811581.1	1692282	PCT/US04/38884 (11/19/2024)
IN	PCT	Granted	2645/DELNP/2006	258236	PCT/US04/38884 (11/19/2024)
JP	PCT	Granted	2006-541422	5087741	PCT/US04/38884 (11/19/2024)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
KR	PCT	Granted	10-2006-7009838	10-1237651	PCT/US04/38884 (11/19/2024)
SG	PCT	Granted	200603355-9	122480	PCT/US04/38884 (11/19/2024)
US	PRO	Expired	60/523420		
US	DIV	Granted	12/512,930	8288127	
63157: IMPROVED EXPRESSION SYSTEMS WITH SEC-SYSTEM SECRETION					
AU	PCT	Granted	2004317306	2004317306	PCT/US04/39316 (11/22/2004)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
CA	PCT	Granted	2546157	2546157	PCT/US04/39316 (11/22/2004)
EP	PCT	Granted	04817876.8	1687324	PCT/US04/39316 (11/22/2004)
GB	EP	Validated	04817876.8	1687324	PCT/US04/39316 (11/22/2004)
FR	EP	Validated	04817876.8	1687324	PCT/US04/39316 (11/22/2004)
IT	EP	Validated	04817876.8	502012902101586 (1687324)	PCT/US04/39316 (11/22/2004)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
DE	EP	Validated	04817876.8	602004039069.0 (1687324)	PCT/US04/39316 (11/22/2004)
IE	EP	Validated	04817876.8	1687324	PCT/US04/39316 (11/22/2004)
CH	EP	Validated	4817876.8	1687324	PCT/US04/39316 (11/22/2004)
EP	DIV	Granted	10179615.9	2327718	PCT/US04/39316 (11/22/2004)
GB	EP	Validated	10179615.9	2327718	PCT/US04/39316 (11/22/2004)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
DE	EP	Validated	10179615.9	602004048897 (2327718)	PCT/US04/39316 (11/22/2004)
PL	EP	Validated	10179615.9	2327718	PCT/US04/39316 (11/22/2004)
EP	DIV	Granted	10179651.4	2336153	PCT/US04/39316 (11/22/2004)
GB	EP	Validated	10179651.4	2336153	PCT/US04/39316 (11/22/2004)
IT	EP	Validated	10179651.4	2336153	PCT/US04/39316 (11/22/2004)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
DE	EP	Validated	10179651.4	602004048957.3 (2336153)	PCT/US04/39316 (11/22/2004)
IN	PCT	Granted	02711/DELNP/2006	252621	PCT/US04/39316 (11/22/2004)
JP	PCT	Granted	2006-541651	5028551	PCT/US04/39316 (11/22/2004)
KR	PCT	Granted	10-2006-7009779	10-1265343	PCT/US04/39316 (11/22/2004)
SG	PCT	Granted	200603356-7	122481	PCT/US04/39316 (11/22/2004)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
US	PRO	Expired	60/524124		
US	ORD	Granted	10/996007	7985564	
63841: PROCESS FOR IMPROVED PROTEIN EXPRESSION BY STRAIN ENGINEERING					
EP	PCT	Issued	05774619.0	1774017	PCT/US05/26390 (7/26/2005)
GB	EP	Validated	05774619.0	1774017	PCT/US05/26390 (7/26/2005)
DE	EP	Validated	05774619.0	602005039591.1	PCT/US05/26390 (7/26/2005)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
EP	DIV	Granted	1117331.7	2412816	PCT/US05/26390 (7/26/2005)
GB	EP	Validated	11173331.7	2412816	PCT/US05/26390 (7/26/2005)
DE	EP	Validated	11173331.7	602005045386.5 (2411816)	PCT/US05/26390 (7/26/2005)
US	PRO	Expired	60/591489		
US	CON	Granted	14/071,273	9,109,229	

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
64111: MANNITOL INDUCED PROMOTER SYSTEMS IN BACTERIAL HOST CELLS					
US	ORD	Granted	11/189375	8,603,824	
AU	PCT	Granted	2006255060	2006255060	PCT/US06/21958 (6/6/2006)
CA	PCT	Granted	2610405	2610405	PCT/US06/21958 (6/6/2006)
CN	PCT	Granted	200680020110.8	ZL200680020110.8	PCT/US06/21958 (6/6/2006)
EP	PCT	Granted	06772320.5	1888763	PCT/US06/21958 (6/6/2006)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
GB	EP	Validated	06772320.5	1888763	PCT/US06/21958 (6/6/2006)
FR	EP	Validated	06772320.5	1888763	PCT/US06/21958 (6/6/2006)
IT	EP	Validated	06772320.5	502015000057763 (1888763)	PCT/US06/21958 (6/6/2006)
DE	EP	Validated	06772320.5	60 2006 046 269.7 (1888763)	PCT/US06/21958 (6/6/2006)
IE	EP	Validated	06772320.5	1888763	PCT/US06/21958 (6/6/2006)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
CH	EP	Validated	06772320.5	1888763	PCT/US06/21958 (6/6/2006)
PL	EP	Validated	06772320.5	1888763	PCT/US06/21958 (6/6/2006)
TR	EP	Validated	06772320.5	1888763	PCT/US06/21958 (6/6/2006)
AT	EP	Validated	06772320.5	1888763	PCT/US06/21958 (6/6/2006)
BE	EP	Validated	06772320.5	1888763	PCT/US06/21958 (6/6/2006)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
IN	PCT	Granted	09206/DELNP/2007	271544	PCT/US06/21958 (6/6/2006)
JP	PCT	Granted	2008-515835	5176114	PCT/US06/21958 (6/6/2006)
SG	PCT	Granted	200718053-2	137574	PCT/US06/21958 (6/6/2006)
US	PRO	Expired	60/687763		
US	ORD	Granted	11/447,553	7476532	

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
US	DIV	Granted	12/330,723	8017355	
65003: BACTERIAL LEADER SEQUENCES FOR INCREASED EXPRESSION					
AU	PCT	Granted	20082105388	2008210538	PCT/US08/52434 (1/30/2008)
CA	PCT	Granted	2677179	2677179	PCT/US08/52434 (1/30/2008)
EP	PCT	Granted	8714119.8	2108047	PCT/US08/52434 (1/30/2008)
GB	EP	Validated	8714119.8	2108047	PCT/US08/52434 (1/30/2008)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
FR	EP	Validated	8714119.8	2108047	PCT/US08/52434 (1/30/2008)
IT	EP	Validated	8714119.8	2108047	PCT/US08/52434 (1/30/2008)
DE	EP	Validated	8714119.8	60 2008 019 589.9 (2108047)	PCT/US08/52434 (1/30/2008)
IE	EP	Validated	8714119.8	2108047	PCT/US08/52434 (1/30/2008)
CH	EP	Validated	8714119.8	2108047	PCT/US08/52434 (1/30/2008)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
EP	DIV	Granted	11194072.2	2468869	PCT/US08/52434 (1/30/2008)
GB	EP	Validated	11194072.2	2468869	PCT/US08/52434 (1/30/2008)
FR	EP	Validated	11194072.2	2468869	PCT/US08/52434 (1/30/2008)
IT	EP	Validated	11194072.2	2468869	PCT/US08/52434 (1/30/2008)
DE	EP	Validated	11194072.2	602008037267.7 (2468869)	PCT/US08/52434 (1/30/2008)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
IE	EP	Validated	11194072.2	2468869	PCT/US08/52434 (1/30/2008)
CH	EP	Validated	11194072.2	2468869	PCT/US08/52434 (1/30/2008)
PL	EP	Validated	11194072.2	2468869	PCT/US08/52434 (1/30/2008)
TR	EP	Validated	11194072.2	TR 2015 06439 T4 (2468869)	PCT/US08/52434 (1/30/2008)
IN	PCT	Granted	4964/DELNP/09	281297	PCT/US08/52434 (1/30/2008)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
JP	PCT	Granted	2009-548414	5714230	PCT/US08/52434 (1/30/2008)
JP	DIV	Granted	2015-047870	649590	PCT/US08/52434 (1/30/2008)
KR	PCT	Granted	10-2009-7017960	10-1491867	PCT/US08/52434 (1/30/2008)
SG	PCT	Granted	200905039-4	154246	PCT/US08/52434 (1/30/2008)
US	PRO	Expired	US60/887486		

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
US	PRO	Expired	60/887476		
US	ORD	Granted	12/022789	7618799	
US	DIV	Granted	12/604,061	7833752	
64569: rPA CODON OPTIMIZATION					
US	PRO	Expired	60/809536		
US	ORD	Granted	11/809,100	8569015	

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
PF0006: METHODS FOR G-CSF PRODUCTION IN A PSEUDOMONAS HOST CELL					
US	PRO	Expired	61/320239		
US	ORD	Granted	13/076,315	8455218	
CA	PCT	Granted	2794740	2794740	PCT/US11/30593 (3/30/2011)
EP	PCT	Granted	11 763 394.1	2552949	PCT/US11/30593 (3/30/2011)
GB	EP	Validated	11 763 394.1	2552949	PCT/US11/30593 (3/30/2011)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
FR	EP	Validated	11 763 394.1	2552949	PCT/US11/30593 (3/30/2011)
DE	EP	Validated	11 763 394.1	60 2011 029 371.0 (2552949)	PCT/US11/30593 (3/30/2011)
CH	EP	Validated	11 763 394.1	2552949	PCT/US11/30593 (3/30/2011)
65570: HIGH LEVEL EXPRESSION OF RECOMBINANT CRM197					
US	PRO	Expired	61/319,152		
AU	ORD	Granted	2010201410	2010201410	

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
KR	ORD	Granted	10-2010-0032638	1739128	
CN	PCT	Granted	201080066026.6	ZL 201080066026.6	PCT/US10/30573 (4/9/2010)
IN	PCT	Granted	7960/DELNP/2012	371175	PCT/US10/30573 (4/9/2010)
PF0007: HIGH LEVEL EXPRESSION OF RECOMBINANT TOXIN PROTEINS					
US	PRO	Expired	61/325235		
US	PRO	Expired	61/319152		

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
US	ORD	Granted	13/073,955	8,530,171	
US	DIV	Granted	13/952,484	8,906,636	
AU	PCT	Granted	2011238711	2011238711	PCT/US11/30227 (3/28/2011)
CA	PCT	Granted	2793978	2,793,978	PCT/US11/30227 (3/28/2011)
CN	PCT	Granted	201180018149.7	ZL201180018149.7	PCT/US11/30227 (3/28/2011)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
BR	PCT	Pending	1120120248987		PCT/US11/30227 (3/28/2011)
EP	PCT	Granted	11766437.5	2553102	PCT/US11/30227 (3/28/2011)
GB	EP	Validated	11766437.5	2553102	PCT/US11/30227 (3/28/2011)
IE	EP	Validated	11766437.5	2553102	PCT/US11/30227 (3/28/2011)
DE	EP	Validated	11766437.5	602011021874.3 (2553102)	PCT/US11/30227 (3/28/2011)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
FR	EP	Validated	11766437.5	2553102	PCT/US11/30227 (3/28/2011)
IT	EP	Validated	11766437.5	502016000010807	PCT/US11/30227 (3/28/2011)
CH	EP	Validated	11766437.5	2553102	PCT/US11/30227 (3/28/2011)
JP	PCT	Granted	2013-502705	5839411	PCT/US11/30227 (3/28/2011)
MX	PCT	Granted	MX/a/2012/011103	343356	PCT/US11/30227 (3/28/2011)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
NZ	PCT	Granted	602958	602958	PCT/US11/30227 (3/28/2011)
65217: APPARATUS AND METHODS FOR OSMOTICALLY SHOCKING CELLS					
KR	PCT	Granted	10-2009-7016786	10-1484337	PCT/US08/00426 (1/11/2008)
PF0009: PROCESS FOR PURIFYING RECOMBINANT PLASMODIUM FALCIPARUM CIRCUMSPOROZOTTE PROTEIN					
US	PRO	Expired	61/641105		
US	ORD	Granted	13/844,261	9,169,304	

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
US	DIV	Granted	14/842,672	9,849,177	
TW	ORD	Granted	102115278	I630213	
VE	ORD	Pending	2013-000490		
NZ	PCT	Granted	630121	630121	PCT/US13/37656 (4/22/2013)
ZA	PCT	Granted	2014/07420	2014/07420	PCT/US13/37656 (4/22/2013)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
MX	PCT	Granted	MX/a/2014/013124	352093	PCT/US13/37656 (4/22/2013)
MY	PCT	Granted	PI 2014003077	MY-166380-A	PCT/US13/37656 (4/22/2013)
SG	PCT	Granted	11201407108T	11201407108T	PCT/US13/37656 (4/22/2013)
CA	PCT	Granted	2870198	2870198	PCT/US13/37656 (4/22/2013)
EP	PCT	Granted	13784680.4	2844666	PCT/US13/37656 (4/22/2013)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
GB	EP	Validated	13784680.4	2844666	PCT/US13/37656 (4/22/2013)
DE	EP	Validated	13784680.4	60 2013 057 931.8 (2844666)	PCT/US13/37656 (4/22/2013)
BE	EP	Validated	13784680.4	2844666	PCT/US13/37656 (4/22/2013)
IT	EP	Validated	13784680.4	502019000076952 (2844666)	PCT/US13/37656 (4/22/2013)
BR	PCT	Granted	11 2014 027019-8	BR112014027019-8	PCT/US13/37656 (4/22/2013)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
AU	PCT	Granted	2013256757	2013256757	PCT/US13/37656 (4/22/2013)
CN	PCT	Granted	201380033337.6	ZL201380033337.6	PCT/US13/37656 (4/22/2013)
JP	PCT	Granted	2015-510319	6238967	PCT/US13/37656 (4/22/2013)
IN	PCT	Granted	9810/DELNP/2014	435114	PCT/US13/37656 (4/22/2013)
KR	PCT	Granted	10-2014-7033423	2087461	PCT/US13/37656 (4/22/2013)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
PF0012: FUSION PARTNERS FOR PEPTIDE PRODUCTION					
US	PRO	Expired	62/086119		
US	ORD	Granted	14/954,766	10118956	
US	DIV	Granted	16/135,875	10981968	
EP	PCT	Granted	EP15866061.3	3227455	PCT/US15/63027 (11/30/2015)
HK	From EP	Pending	18104633.5		

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
AU	PCT	Granted	2015355242	2015355242	PCT/US15/63027 (11/30/2015)
CA	PCT	Granted	2966358	2966358	PCT/US15/63027 (11/30/2015)
TW	ORD	Granted	104140109	I702289	
BR	PCT	Pending	BR 11 2017 011662 6		PCT/US15/63027 (11/30/2015)
CN	PCT	Granted	201580064973.4	107532190	PCT/US15/63027 (11/30/2015)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
CN	DIV	Pending	202110725675.2		PCT/US15/63027 (11/30/2015)
IN	PCT	Pending	201717015496		PCT/US15/63027 (11/30/2015)
JP	PCT	Granted	2017-530121	6817939	PCT/US15/63027 (11/30/2015)
JP	DIV	Granted	2020-148237	7148579	PCT/US15/63027 (11/30/2015)
KR	PCT	Granted	10-2017-7017007	10-2353262	PCT/US15/63027 (11/30/2015)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
MX	PCT	Granted	MX/a/2017/006866	386884	PCT/US15/63027 (11/30/2015)
NZ	PCT	Granted	732400	732400	PCT/US15/63027 (11/30/2015)
SG	PCT	Granted	11201704362V	11201704362V	PCT/US15/63027 (11/30/2015)
PF0018: METHOD FOR PRODUCTION OF RECOMBINANT E. COLI ASPARAGINASE					
US	PRO	Expired	62/578,302		
US	ORD	Granted	16/163,398	10662433	

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
US	CON	Granted	16/849,532	11046964	
JP	PCT	Pending	2020-523340		PCT/US18/56375 (10/17/2018)
SG	PCT	Pending	11202003614W		PCT/US18/56375 (10/17/2018)
EP	PCT	Pending	18870109.8		PCT/US18/56375 (10/17/2018)
AU	PCT	Granted	2018354068	2018354068	PCT/US18/56375 (10/17/2018)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
CN	PCT	Pending	201880069962.9		PCT/US18/56375 (10/17/2018)
IN	PCT	Pending	202017010092		PCT/US18/56375 (10/17/2018)
PF0019: BACTERIAL LEADER SEQUENCES FOR PERIPLASMIC PROTEIN EXPRESSION					
US	PRO	Expired	62/578,304		
US	ORD	Pending	16/163,421		
CA	PCT	Pending	3077393		PCT/US18/56376 (10/17/2018)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
EP	PCT	Pending	18870110.6		PCT/US18/56376 (10/17/2018)
AU	PCT	Pending	2018354069		PCT/US18/56376 (10/17/2018)
IN	PCT	Pending	202017013832		PCT/US18/56376 (10/17/2018)
KR	PCT	Pending	10-2020-7015248		PCT/US18/56376 (10/17/2018)
NZ	PCT	Pending	764618		PCT/US18/56376 (10/17/2018)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
[REDACTED]					
[REDACTED]		[REDACTED]			
[REDACTED]					
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]		

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
█	█	█	█		
█	█	█	█		
█	█	█	█		█
█	█	█	█		█

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
■	■	■	■		■
■	■	■			■
■	■	■	■		■
PF0024: BACTERIAL HOSTS FOR RECOMBINANT PROTEIN EXPRESSION					
US	PRO	Expired	63/209239		
US	ORD	Pending	17/836,919		

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
PF0027: ANTHRAX VACCINE					
PCT	PCT	Pending	PCT/US22/32911 (6-9-2022)		
US	PRO	Expired	63/209,284		
PCT	PCT	Pending	PCT/US22/32212 (6-3-2022)		
[REDACTED]					
[REDACTED]					
[REDACTED]		[REDACTED]			

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
[REDACTED]					
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]		
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]		
68745: PRODUCTION OF RECOMBINANT PROTEINS UTILIZING NON-ANTIBIOTIC SELECTION METHODS AND THE INCORPORATION OF NON-NATURAL AMINO ACIDS THEREIN					
EP	PCT	Granted	10775323.8	2430164	PCT/US10/34201 (5/10/2010)
BE	EP	Validated	10775323.8	2430164	PCT/US10/34201 (5/10/2010)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
FR	EP	Validated	10775323.8	2430164	PCT/US10/34201 (5/10/2010)
DE	EP	Validated	10775323.8	60 2010 043 751.5 (2430164)	PCT/US10/34201 (5/10/2010)
GB	EP	Validated	10775323.8	2430164	PCT/US10/34201 (5/10/2010)
IE	EP	Validated	10775323.8	2430164	PCT/US10/34201 (5/10/2010)
IT	EP	Validated	10775323.8	2430164	PCT/US10/34201 (5/10/2010)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
NL	EP	Validated	10775323.8	2430164	PCT/US10/34201 (5/10/2010)
ES	EP	Validated	10775323.8	2430164	PCT/US10/34201 (5/10/2010)
CA	PCT	Granted	2761578	2761578	PCT/US10/34201 (5/10/2010)
AU	PCT	Granted	2010247938	2010247938	PCT/US10/34201 (5/10/2010)
AU	PCT	Granted	2016203224	2016203224	PCT/US10/34201 (5/10/2010)

Project Pelican Patent Schedule
Privileged and Confidential

Country	Case Type	Status	Appl. Number	Patent Number	PCT Number (filing date)
IN	PCT	Granted	02335/MUMNP/11	333846	PCT/US10/34201 (5/10/2010)
NZ	PCT	Granted	596283	596283	PCT/US10/34201 (5/10/2010)
US	PRO	Expired	61/177267		
US	PCT	Granted	13/319844	9243253	PCT/US10/34201 (5/10/2010)
US	CON	Granted	14/974,897	9708616	PCT/US10/34201 (5/10/2010)